MLH1高甲基化与MLH1「Lynch样」错配修复基因突变子宫内膜癌患者的不同结局及免疫检查点抑制剂反应
对1673例错配修复缺陷子宫内膜肿瘤行二代测序和全转录组测序,比较MLH1高甲基化(89.2%)与MLH1突变(10.8%)肿瘤的生存、免疫检查点抑制剂反应及分子特征。MLH1高甲基化肿瘤总生存更差,免疫微环境更「冷」,TP53和DNA损伤修复基因突变率降低而JAK1、FGFR2、CCND1、PTEN突变率及ER/PR阳性率升高。
要点
- MLH1高甲基化占错配修复缺陷子宫内膜癌的89.2%,MLH1突变占10.8%。
- MLH1高甲基化肿瘤总生存显著更差,ICI治疗后总生存呈更差趋势。
- MLH1高甲基化肿瘤PD-L1阳性、免疫细胞浸润及IFNγ评分均降低。
核心结论
- MLH1高甲基化子宫内膜癌患者较MLH1突变患者生存显著更差且免疫治疗反应存在差异,与不同突变谱、更免疫「冷」表型及ER/PR表达升高相关。
研究设计与样本
- 对1673例错配修复缺陷子宫内膜肿瘤行二代测序和全转录组测序(Caris Life Sciences,Phoenix,AZ)。
- PD-L1、ER、PR采用免疫组化检测,免疫细胞浸润采用MCP-counter计算。
- 采用卡方检验和Mann-Whitney U检验并校正多重比较,总生存采用Kaplan-Meier生存曲线描绘。
主要发现
- 子宫内膜癌队列中MLH1高甲基化肿瘤占89.2%,MLH1突变肿瘤占10.8%,中位年龄分别为67岁和60岁(p < 0.01)。
- MLH1高甲基化肿瘤患者总生存显著更差,ICI治疗后总生存呈更差趋势。
- MLH1高甲基化较MLH1突变肿瘤PD-L1阳性率、免疫检查点基因表达、免疫细胞浸润、T细胞炎症评分及干扰素γ(IFNγ)评分均降低。
- MLH1高甲基化与TP53和DNA损伤修复基因突变率降低相关,与JAK1、FGFR2、CCND1、PTEN突变率升高及ER、PR阳性率升高相关。
临床怎么用
- 作者认为,对于MLH1高甲基化肿瘤患者,提供者可考虑早期从单药ICI转换为多药方案或激素治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify differential survival outcomes and immune checkpoint inhibitor (ICI) response in MLH1 hypermethylated versus MLH1 mutated ("Lynch-like") endometrial tumors and determine whether their molecular profiles can elucidate the differential outcomes. METHODS: 1673 mismatch repair deficient endometrial tumors were analyzed by next-generation sequencing and whole transcriptome sequencing (Caris Life Sciences, Phoenix, AZ). PD-L1, ER, and PR were tested by immunohistochemistry and immune cell infiltrates were calculated using MCP-counter. Significance was determined using Chi-square and Mann-Whitney U tests and adjusted for multiple comparisons. Overall survival (OS) was depicted using Kaplan-Meier survival curves. RESULTS: The endometrial cancer cohort comprised 89.2% patients with MLH1 hypermethylated tumors and 10.8% with MLH1 mutated tumors, with median ages of 67 and 60 years, respectively (p < 0.01). Patients with MLH1 hypermethylated tumors had significantly worse OS and trended toward worse OS following ICI treatment than patients with MLH1 mutated tumors. The immune microenvironment of MLH1 hypermethylated relative to MLH1 mutated was characterized by decreased PD-L1 positivity, immune checkpoint gene expression, immune cell infiltration, T cell inflamed scores, and interferon gamma (IFNγ) scores. MLH1 hypermethylation was also associated with decreased mutation rates in TP53 and DNA damage repair genes, but increased rates of JAK1, FGFR2, CCND1, and PTEN mutations, as well as increased ER and PR positivity. CONCLUSIONS: Endometrial cancer patients with MLH1 hypermethylation display significantly decreased survival and discrepant immunotherapy responses compared to patients with MLH1 mutated tumors, which was associated with differential mutational profiles, a more immune cold phenotype, and increased ER/PR expression in MLH1 hypermethylated tumors. Providers may consider early transition from single agent ICI to a multi-agent regimen or hormonal therapy for patients with MLH1 hypermethylated tumors.
引用
- Toboni MD, Wu S, Farrell A, et al. Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutation. Gynecol Oncol. 2023. PMID: 37683549. doi:10.1016/j.ygyno.2023.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。